These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16324089)

  • 1. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
    Péchevis M; Clarke CE; Vieregge P; Khoshnood B; Deschaseaux-Voinet C; Berdeaux G; Ziegler M;
    Eur J Neurol; 2005 Dec; 12(12):956-63. PubMed ID: 16324089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries.
    Hechtner MC; Vogt T; Zöllner Y; Schröder S; Sauer JB; Binder H; Singer S; Mikolajczyk R
    Parkinsonism Relat Disord; 2014 Sep; 20(9):969-74. PubMed ID: 24953743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
    Dodel RC; Berger K; Oertel WH
    Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
    Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Tison F; Rascol O;
    Eur J Neurol; 2017 Dec; 24(12):1532-1538. PubMed ID: 28940893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia.
    Suh DC; Pahwa R; Mallya U
    J Neurol Sci; 2012 Aug; 319(1-2):24-31. PubMed ID: 22664154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the motor complications of Parkinson's disease on the quality of life.
    Chapuis S; Ouchchane L; Metz O; Gerbaud L; Durif F
    Mov Disord; 2005 Feb; 20(2):224-30. PubMed ID: 15384126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
    Puente V; De Fabregues O; Oliveras C; Ribera G; Pont-Sunyer C; Vivanco R; Cucurella G; Giralt E; Delgado T; Garcia C; Seoane A; Campo R
    Parkinsonism Relat Disord; 2010 Mar; 16(3):218-21. PubMed ID: 19762271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Duodopa
    Ciurleo R; Corallo F; Bonanno L; Lo Buono V; Di Lorenzo G; Versaci R; Allone C; Palmeri R; Bramanti P; Marino S
    J Neurol; 2018 Sep; 265(9):2005-2014. PubMed ID: 29951701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
    Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
    Grandas F; Hernández B;
    Eur J Neurol; 2007 Mar; 14(3):282-9. PubMed ID: 17355548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.